Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8759620 | 0.86 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL8635512 | 0.84 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL14009819 | 0.82 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL6053843 | 0.81 | TSHR (0.44) | KMT2AMEN1KDM4ENQO1 | |
| SCHEMBL4172466 | 0.79 | KMT2A (0.40) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL9055584 | 0.79 | CYP2C9 (0.55) | MAPT | |
| SCHEMBL8759510 | 0.79 | ALDH1A3 (0.51) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL342467 | 0.78 | NQO1 (0.64) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL4386273 | 0.78 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL13538696 | 0.77 | RAB9A (0.43) | ALDH1A1KMT2AMEN1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. | 2006-04-13 | — | — | US | disclosed |
| EP-1620109-A2 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1617848-A2 | ANTI-CANCER PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050261253-A1 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096234-A2 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-0652884-B1 | PHOSPHONATED ARYLETHANOLAMINE COMPOUNDS WITH ANTI-HYPERGLYCEMIC AND/OR ANTI-OBESITY ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1997-05-28 | — | — | EP | disclosed |
| US-5519006-A | Phosphonated arylethanolamine compounds with anti-hyperglycemic and/or anti-obesity activity | SMITHKLINE BEECHAM PLC (GB) | 1996-05-21 | — | — | US | disclosed |
| EP-0652884-A1 | PHOSPHONATED ARYLETHANOLAMINE COMPOUNDS WITH ANTI-HYPERGLYCEMIC AND/OR ANTI-OBESITY ACTIVITY. | SMITHKLINE BEECHAM PLC (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002493-A1 | PHOSPHONATED ARYLETHANOLAMINE COMPOUNDS WITH ANTI-HYPERGLYCEMIC AND/OR ANTI-OBESITY ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261253-A1 | Kinase inhibitory phosphonate analogs | PIK3CA, PNKP, PIK3CB | ALDH1A1 4596/4885SMN1; SMN2 4005/4885LMNA 2617/4885 |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | PIK3CA, PHOSPHO1, PTEN | ALDH1A1 3678/4885SMN1; SMN2 3947/4885LMNA 2680/4885 |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | PIK3CA, PNKP, PIK3CB | ALDH1A1 4596/4885SMN1; SMN2 4005/4885LMNA 2617/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | ALDH1A1 3678/4885SMN1; SMN2 3947/4885LMNA 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.